688385:SSEShanghai Fudan Microelectronics Group Co., Ltd. Class A Analysis
Data as of 2026-05-28 - not real-time
CN¥66.45
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Shanghai Fudan Microelectronics is trading at a staggering PE of 237 versus an industry average of 40, while the DCF‑derived fair value sits around 13.8 CNY—far below the current price of 66.45 CNY. The stock shows a bullish technical backdrop with the 20‑day SMA (70.47) above the 50‑day SMA (70.13) and a reported trend direction of bullish, yet the MACD line remains in bearish territory and the RSI hovers at 42, indicating limited upside momentum. Volume is increasing, supporting the short‑term price stability near the identified support level of 65.18 CNY, but the 30‑day volatility of over 53% and a beta of 0.55 signal pronounced price swings. Fundamentals reveal modest revenue growth of 16% and a gross margin of 45%, but profitability is thin with a net margin of only 5.9% and a ROE of 3.1%. The balance sheet is strained: debt‑to‑equity stands at 20.3, and total debt (1.40 B CNY) exceeds cash (1.54 B CNY) only marginally, raising concerns about leverage. Dividend yield is negligible at 0.12% with a payout ratio of 28.6%, suggesting dividend sustainability but limited income appeal. Overall, the stock appears dramatically overvalued, vulnerable to sector cyclicality, regulatory shifts in China’s semiconductor space, and high price volatility, making a cautious stance prudent.
Given the extreme valuation gap, the technical bullish bias is unlikely to sustain without a catalyst. Investors should weigh the high‑growth narrative against the stark overvaluation and the company’s modest cash generation. The elevated volatility and moderate beta imply that price movements could be abrupt, especially if macro‑economic or policy changes affect the Chinese tech sector. In the near term, the price is near support and may hold, but medium‑ to long‑term expectations hinge on the company delivering earnings growth that justifies its premium—a scenario that currently seems improbable.
Given the extreme valuation gap, the technical bullish bias is unlikely to sustain without a catalyst. Investors should weigh the high‑growth narrative against the stark overvaluation and the company’s modest cash generation. The elevated volatility and moderate beta imply that price movements could be abrupt, especially if macro‑economic or policy changes affect the Chinese tech sector. In the near term, the price is near support and may hold, but medium‑ to long‑term expectations hinge on the company delivering earnings growth that justifies its premium—a scenario that currently seems improbable.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price hovering just above the identified support level
- increasing volume supporting short‑term stability
- technical bullish trend despite bearish MACD
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- massive valuation gap between market price and DCF fair value
- thin profitability margins and modest cash flow generation
- persistent sector cyclicality and regulatory uncertainty
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- overvaluation unlikely to be justified by earnings growth
- high leverage relative to cash reserves
- exposure to Chinese semiconductor policy and market volatility
Key Metrics & Analysis
Financial Health
Revenue Growth16.20%
Profit Margin5.92%
P/E Ratio237.3
ROE3.14%
ROA1.11%
Debt/Equity20.32
P/B Ratio8.7
Op. Cash FlowCN¥1.1B
Free Cash FlowCN¥436.1M
Industry P/E40.4
Technical Analysis
TrendBullish
RSI42.8
SupportCN¥65.18
ResistanceCN¥76.67
MA 20CN¥70.47
MA 50CN¥70.13
MA 200CN¥67.21
MACDBearish
VolumeIncreasing
Fear & Greed Index92.34
Valuation
Fair ValueCN¥13.78
GradeOvervalued
TypeGrowth
Dividend Yield0.12%
Risk Assessment
Beta0.55
Volatility53.37%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.